ASH 2024 featured practice-changing studies in lymphoid malignancies, including tafasitamab’s impact in FL, ibrutinib’s OS benefit in MCL, and promising epcoritamab data in CLL.

Researchers explore the cellular and molecular adaptations associated with human secondary lymphoid tissue in adults during ...

Bacteria in the gut have been implicated in autoimmune diseases, like lupus, that don't primarily affect the gastrointestinal ...